| Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell … J Bellmunt, C Théodore, T Demkov, B Komyakov, L Sengelov, ... J Clin Oncol 27 (27), 4454-4461, 2009 | 854 | 2009 |
| European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I S Krege, J Beyer, R Souchon, P Albers, W Albrecht, F Algaba, M Bamberg, ... European urology 53 (3), 478-496, 2008 | 764 | 2008 |
| Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin … M De Santis, J Bellmunt, G Mead, JM Kerst, M Leahy, P Maroto, T Gil, ... Journal of clinical oncology 30 (2), 191, 2012 | 749 | 2012 |
| European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) HJ Schmoll, R Souchon, S Krege, P Albers, J Beyer, C Kollmannsberger, ... Annals of Oncology 15 (9), 1377-1399, 2004 | 661 | 2004 |
| Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics: Perception versus reality SM Grunberg, RR Deuson, P Mavros, O Geling, M Hansen, G Cruciani, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 655 | 2004 |
| Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration W Abida, A Patnaik, D Campbell, J Shapiro, AH Bryce, R McDermott, ... Journal of Clinical Oncology 38 (32), 3763-3772, 2020 | 557 | 2020 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 520 | 2018 |
| Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior … J Bellmunt, H von der Maase, GM Mead, I Skoneczna, M De Santis, ... Journal of Clinical Oncology 30 (10), 1107, 2012 | 506 | 2012 |
| Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours J Pedersen-Bjergaard, G Daugaard, SW Hansen, M Rørth, P Philip, ... The Lancet 338 (8763), 359-363, 1991 | 439 | 1991 |
| Testicular cancer L Cheng, P Albers, DM Berney, DR Feldman, G Daugaard, T Gilligan, ... Nature Reviews Disease Primers 4 (1), 29, 2018 | 430 | 2018 |
| Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label … CN Sternberg, I Skoneczna, JM Kerst, P Albers, SD Fossa, M Agerbaek, ... The lancet oncology 16 (1), 76-86, 2015 | 397 | 2015 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 379 | 2015 |
| Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA S Oudard, K Fizazi, L Sengeløv, G Daugaard, F Saad, S Hansen, ... Journal of Clinical Oncology 35 (28), 3189-3197, 2017 | 371 | 2017 |
| Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up K Fizazi, FA Greco, N Pavlidis, G Daugaard, K Oien, G Pentheroudakis Annals of Oncology 26, v133-v138, 2015 | 348 | 2015 |
| Cisplatin nephrotoxicity: a review G Daugaard, U Abildgaard Cancer chemotherapy and pharmacology 25, 1-9, 1989 | 336 | 1989 |
| Testicular cancer survivorship: research strategies and recommendations LB Travis, C Beard, JM Allan, AA Dahl, DR Feldman, J Oldenburg, ... Journal of the national cancer institute 102 (15), 1114-1130, 2010 | 324 | 2010 |
| Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ... Annals of oncology 24 (4), 878-888, 2013 | 320 | 2013 |
| ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up F Honecker, J Aparicio, D Berney, J Beyer, C Bokemeyer, R Cathomas, ... Annals of oncology 29 (8), 1658-1686, 2018 | 300 | 2018 |
| Cisplatin and hypomagnesemia H Lajer, G Daugaard Cancer treatment reviews 25 (1), 47-58, 1999 | 297 | 1999 |
| Muscle dysfunction in cancer patients JF Christensen, LW Jones, JL Andersen, G Daugaard, M Rorth, P Hojman Annals of oncology 25 (5), 947-958, 2014 | 271 | 2014 |
